Compare YAAS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YAAS | KALA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.0M |
| IPO Year | 2024 | 2017 |
| Metric | YAAS | KALA |
|---|---|---|
| Price | $1.57 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 77.1K | ★ 2.2M |
| Earning Date | 02-15-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $581,862.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.51 |
| 52 Week High | $560.00 | $20.60 |
| Indicator | YAAS | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 41.28 |
| Support Level | $1.53 | $0.58 |
| Resistance Level | $1.72 | $0.71 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 9.12 | 14.22 |
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.